Title |
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
|
---|---|
Published in |
Cancer Chemotherapy and Pharmacology, September 2014
|
DOI | 10.1007/s00280-014-2575-9 |
Pubmed ID | |
Authors |
Ami V. Desai, Elizabeth Fox, L. Mary Smith, Allison Pecha Lim, John M. Maris, Frank M. Balis |
Abstract |
Ch14.18 improves survival in children with high-risk neuroblastoma but is associated with substantial toxicity. Ch14.18 pharmacokinetics were previously reported to be highly variable and characterized by a higher clearance in children than in adults, and a large volume of distribution. Identifying factors responsible for its variability could lead to alternative dosing strategies that reduce toxicity. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 30 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 19% |
Student > Ph. D. Student | 6 | 19% |
Researcher | 3 | 10% |
Professor | 3 | 10% |
Student > Master | 2 | 6% |
Other | 3 | 10% |
Unknown | 8 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 26% |
Immunology and Microbiology | 5 | 16% |
Biochemistry, Genetics and Molecular Biology | 4 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
Agricultural and Biological Sciences | 2 | 6% |
Other | 1 | 3% |
Unknown | 8 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2014.
All research outputs
#16,049,105
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#1,859
of 2,501 outputs
Outputs of similar age
#143,734
of 245,001 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#16
of 30 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 245,001 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.